Valuation
- Market cap
- 275,588,000
- Revenue TTM
- $6,650,000
- Net income TTM
- $-136,320,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -2,049.92%
- Debt to equity
- 0.00
Trading
- Volume
- 658,000
- Avg volume
- 1,665,440
- Day's range
- $2.27 – $2.36
- Shares out
- 119,821,000
- Stochastic %K
- 14%
- Beta
- 2.52
- Analysts
- Sell
- Price target
- $5.74
Company profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell progr...
Show more
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 875 1800
- Website
- https://www.fatetherapeutics.com
- Address
- 12278 Scripps Summit Drive, San Diego, United States
Latest news
No headlines yet.
